Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06116890
Other study ID # 4951-002
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 31, 2024
Est. completion date December 2025

Study information

Verified date May 2024
Source Kyowa Kirin Co., Ltd.
Contact Kyowa Kirin, Inc.
Phone 1-609-919-1100
Email kkd.clintrial.82@kyowakirin.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date December 2025
Est. primary completion date November 2025
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - Voluntary written informed consent to participate in the study - Active subfoveal MNV (any subtype) or juxtafoveal MNV secondary to AMD with leakage affecting the fovea in the study eye at screening - BCVA ETDRS letter score of 73 letters to 35 letters in the study eye as measured by the ETDRS visual acuity chart at screening - CST = 350 µm and = 450 µm at screening Exclusion Criteria: - Subretinal hemorrhage, fibrosis, or atrophy of > 50% of the total lesion area and/or that involves the fovea in the study eye - Uncontrolled glaucoma in the study eye - Aphakia or pseudophakia with AC-IOL in the study eye - Active intraocular inflammation in the study eye - Any current ocular condition for which visual acuity loss would not improve from resolution of macular edema in the study eye - History of rhegmatogenous retinal detachment in the study eye - Any current or history of ocular disease other than nAMD in the study eye that may confound assessment of the macula or affect central vision - History of the following therapies in the study eye: - History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD - Prior treatment PDT with Visudyne®, external-beam radiation therapy, transpupillary thermotherapy, or panretinal photocoagulation - Previous use of periocular or intraocular (sub-Tenon or IVT) corticosteroids - Previous intraocular device implantation except PC-IOL - Previous laser (any type) to the macular area - Previous treatment with any IVT anti-VEGF drugs - Any current or history of endophthalmitis in either eye - History of idiopathic or autoimmune-associated uveitis in either eye - Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
KHK4951
KHK4951 eye drop for 44 weeks until end of the trial
Aflibercept Injection
Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol

Locations

Country Name City State
Australia Adelaide Eye and Retina Centre Adelaide South Australia
Australia Eye Clinic Albury Wodonga Albury New South Wales
Australia Centre for Eye Research Australia East Melbourne Victoria
Australia Marsden Eye Specialists Parramatta New South Wales
Australia Strathfield Retina Clinic Strathfield New South Wales
Australia Sydney Eye Hospital Sydney New South Wales
Japan The University of Tokyo Hospital Bunkyo-Ku Tokyo
Japan Nihon University Hospital Chiyoda-ku Tokyo
Japan Hayashi Eye Hospital - Ophthalmology Fukuoka-shi Fukuoka
Japan Fukushima Medical University Hospital - Ophthalmology Fukushima
Japan Tokyo Medical University Hachioji Medical Center Hachioji Tokyo
Japan Kansai Medical University Medical Center Hirakata Osaka
Japan Nara Medical University Hospital - Ophthalmology Kashihara Nara
Japan Kagawa University Hospital Kita-gun Tokyo
Japan Kobe University Hospital - Ophthalmology Kobe Hyôgo
Japan Minamitohoku Eye Clinic Koriyama Fukushima
Japan Kurume University Hospital Kurume Fukuoka
Japan Rakuwakai Otowa Hospital Kyoto
Japan Shinshu University Hospital - Ophthalmology Matsumoto Nagano
Japan Matsuyama Red Cross Hospital Matsuyama Shizuoka
Japan Tokyo Medical Center Meguro-ku Tokyo-to
Japan Kozawa Eye Hospital and Diabetes Center Mito Ibaraki
Japan Aichi Medical University Hospital - Ophthalmology Nagakute Aiti [Aichi]
Japan MIYAKE Eye Hospital Nagoya Aiti
Japan University of the Ryukyus Hospital Nakagami-gun Okinawa
Japan Okayama University Hospital - Ophthalmology Okayama
Japan Osaka Metropolitan University Hospital Osaka Ôsaka
Japan Kindai University Hospital Osakasayama-shi Osaka
Japan Saitama Red Cross Hospital Saitama
Japan Toho University Medical Center Sakura Hospital Sakura Chiba
Japan Caress Sapporo Tokeidai Memorial Hospital Sapporo Hokkaido
Japan Jichi Medical University Hospital Shimotsuke Tochigi
Japan Keio University Hospital - Ophthalmology Shinjuku-ku Tôkyô
Korea, Republic of Keimyung University Dongsan Hospital Daegu Daegu Gwang'yeogsi
Korea, Republic of Yeungnam University Hospital Daegu Daegu Gwang'yeogsi
Korea, Republic of Gachon University Gil Medical Center Incheon Incheon Gwang'yeogsi
Korea, Republic of Seoul National University Bundang Hospital Seongnam Gyeonggido
Korea, Republic of CHA Bundang Medical Center, CHA University Seongnam-si Gyeonggido
Korea, Republic of Asan Medical Center Seoul Seoul Teugbyeolsi
Korea, Republic of Kim Eye Hospital Seoul Seoul Teugbyeolsi
Korea, Republic of Korea University Anam Hospital Seoul Seoul Teugbyeolsi
Korea, Republic of Kyung Hee University Hospital Seoul Seoul Teugbyeolsi
Korea, Republic of Samsung Medical Center Seoul Seoul Teugbyeolsi
Korea, Republic of Seoul National University Hospital Seoul Seoul Teugbyeolsi
Korea, Republic of Severance Hospital, Yonsei University Health System Seoul Seoul Teugbyeolsi
Korea, Republic of The Catholic University of Korea, Seoul St. Mary's Hospital Seoul Seoul Teugbyeolsi
United States Retina Research Institute of Texas Abilene Texas
United States Vision Research Center Eye Associates of New Mexico Albuquerque New Mexico
United States Win Retina Arcadia California
United States Southeast Retina Center Augusta Georgia
United States Austin Clinical Research, LLC Austin Texas
United States Austin Retina Associates - Ophthalmology/Retina (RCA Network site) Austin Texas
United States Retina Consultants of Texas Bellaire Texas
United States Retina Vitreous Associates Medical Group Beverly Hills California
United States Retina Center of New Jersey Bloomfield New Jersey
United States Massachusetts Eye and Ear Boston Massachusetts
United States Blue Ocean Clinical Research West Clearwater Florida
United States Retina Consultants of Southern CO Colorado Springs Colorado
United States Retina Vitreous Center in Edmond Oklahoma Edmond Oklahoma
United States The Retina Partners Encino California
United States Retina Group of Washington Fairfax Virginia
United States Texas Retina Associates Fort Worth Texas
United States Charles Retina Institute Germantown Tennessee
United States Salehi Retina Institute, Inc Huntington Beach California
United States Eye Care Specialists Kingston Pennsylvania
United States Charleston Neuroscience Institute (RCA Network Site) Ladson South Carolina
United States Retina Vitreous Surgeons of Central NY, PC Liverpool New York
United States Florida Eye Associates Melbourne Florida
United States Barnet Dulaney Perkins Eye Center - Phoenix Mesa Arizona
United States Ophthalmic Consultants of Long Island Oceanside New York
United States Payam Amini Pasadena California
United States Eye Associates of Pinellas Pinellas Park Florida
United States Ft. Lauderdale Eye Institute Plantation Florida
United States Eye Health Northwest Portland Oregon
United States Black Hills Regional Eye Institute - Ophthalmology Rapid City South Dakota
United States Sierra Eye Associates Reno Nevada
United States Associated Retinal Consultants (ARC) P.C. - Opthalmology Royal Oak Michigan
United States Retina Vitreous Associates of Florida - Saint Petersburg Saint Petersburg Florida
United States Retinal Consultants of Texas- San Antonio (RCA Network site) San Antonio Texas
United States Retina Consultants of Texas (RCA Network Site) The Woodlands Texas
United States Retina Associates Southwest, P.C. Tucson Arizona
United States Strategic Clinical Research Group, LLC Willow Park Texas
United States Center for Retina and Macular Disease - Ophthalmology Winter Haven Florida

Sponsors (1)

Lead Sponsor Collaborator
Kyowa Kirin, Inc.

Countries where clinical trial is conducted

United States,  Australia,  Japan,  Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of participants with adverse events For 44 weeks until the end of the trial
Other Serum KHK4951 concentration 44 Weeks
Primary Reduction of 15 or more letters in BCVA (Best corrected visual acuity) as measured by ETDRS visual acuity chart from baseline For 44 weeks until the end of the trial
Secondary The number of aflibercept IVT For 44 weeks until the end of the trial
Secondary Change from baseline in SHRM as measured by SD-OCT 44 weeks
Secondary Change from baseline in retinal morphology as measured by SD-OCT 44 weeks
Secondary Change from baseline in MNV lesion area and total MNV leakage area as measured by FA 44 Weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04543331 - Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
Recruiting NCT05904691 - Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration Phase 1
Completed NCT05282004 - Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit Phase 3
Active, not recruiting NCT04764656 - Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal
Completed NCT05269966 - Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) Phase 4
Completed NCT05161806 - Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe Phase 3
Recruiting NCT04657289 - A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) Phase 3
Recruiting NCT06075147 - The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
Terminated NCT04746963 - Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration Phase 1/Phase 2
Recruiting NCT05769153 - Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) Phase 1/Phase 2
Enrolling by invitation NCT05210803 - Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
Recruiting NCT04514653 - RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) Phase 2
Not yet recruiting NCT06398080 - An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
Active, not recruiting NCT05989126 - Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) Phase 3